Skip Navigation


Rheumatology Advance Access originally published online on August 24, 2004
Rheumatology 2004 43(12):1463-1464; doi:10.1093/rheumatology/keh356
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
43/12/1463    most recent
keh356v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Griffiths, I.
Right arrow Articles by Scott, D. G. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Griffiths, I.
Right arrow Articles by Scott, D. G. I.
Related Collections
Right arrow Rheumatoid Arthritis
Right arrow Health Economics
Right arrow Education
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology Vol. 43 No. 12 © British Society for Rheumatology 2004; all rights reserved

EDITORIAL

BSR Biologics Registry

I. Griffiths, A. Silman, D. Symmons1 and D. G. I. Scott2

BSR Biologics Registry Management Committee, 1 ARC Epidemiology Unit, Manchester University Medical School, Manchester and 2 British Society for Rheumatology, London, UK

Correspondence to: I. Griffiths. E-mail: ian.griffiths@nuth.northy.nhs.uk

The first 150 words of the full text of this article appear below.

The recognition of the pivotal role of inflammatory cytokines in the pathogenesis of rheumatoid arthritis, the development of specific antagonists, the demonstration of their clinical effectiveness and the subsequent commercial production and licensing of these agents have been the major achievements in rheumatology over the past decade. However, uncertainties remain regarding the short- and long-term safety of these agents, initially TNF-{alpha} inhibitors. Also, their significant cost, some tenfold greater than that of the previous most expensive agent, did impact on the use of these drugs in a cost-constrained health-care system such as the NHS. The British Society for Rheumatology (BSR) in April 2000 took the bold and imaginative step of producing clinical guidelines that recommended thresholds for both commencing therapy and continuing therapy in those who respond. It also suggested the establishment of a national registry of patients on biologic therapy to evaluate the safety of these agents [1. . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Pathol.Home page
S. L Johnston
Biologic therapies: what and when?
J. Clin. Pathol., January 1, 2007; 60(1): 8 - 17.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
L. J. Kay, I. D. Griffiths, and for the BSR Biologics Register Management committe
UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register
Rheumatology, November 1, 2006; 45(11): 1376 - 1379.
[Abstract] [Full Text] [PDF]